A Phase 2/3 interventional study of propranolol in Infantile Hemangioma, sponsored by West China Hospital. Recruiting at 3 sites in China. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by West China Hospital · Phase 2/3, Interventional, and Treatment
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
Infantile hemangioma (IH) is the most common benign tumor in infants, with an estimated prevalence of 4%-5%. Although most IH resolves over time without serious sequelae, a significant proportion can lead to serious complications such as ulcers. Propranolol is considered to be an effective treatment modality for ulceration IH, and there are retrospective studies suggesting that starting treatment at a low dose is safe and effective. However, due to the lack of prospective study, the effectiveness of different doses of propranolol for initiating treatment of ulceration IH is unknown. Therefore, a prospective study of ulceration IHs in Chinese children was conducted to clarify its efficacy.
33 studies on the registry are indexed under Hemangioma, Capillary; 5 are open to participants now.
This study's planned enrollment of 32 is below the median of 78 across 20 interventional studies indexed under Hemangioma, Capillary.
Browse Hemangioma, Capillary studies →West China Hospital is the lead sponsor of 501 studies on the registry; 246 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1mg/kg/d
Drug: propranolol
2mg/kg/d
Drug: propranolol
different dose
Time to ulcer healing
Time from the start of treatment with propranolol to complete ulcer healing
Time frame: 0.5 years
The resolution of IH at month 6 after treatment
complete resolution/complete resolution/partial resolution/no effect/withdrawal from treatment
Time frame: 0.5 years
adverse events
The incidence of adverse events in the two groups after oral propranolol at different doses
Time frame: 0.5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Sep 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Propranolol